Ryotaro Ishikawa Oka

Global Market Access Director
Novartis

Ryotaro is a senior executive with 20 years of functional experience in marketing, sales and key account management. He led the Global Excellence Tendering Initiative in Novartis and also successfully implemented innovative pricing models for the company in Latin-America. He has designed and implemented the market access strategies for many global product launches and has helped to broaden access to markets in specialty and primary care segments. Ryotaro believes that the pharma ecosystem is facing a time of great change and learning. Many paradigms will be broken, and new ones will appear. Joint efforts between government, medical organisations, patients and industry will create new solutions that provide better health to patients.

Check out the incredible speaker line-up to see who will be joining Ryotaro.

Download The Latest Agenda

Day Two, 24th September 2020

Thursday, September 24th, 2020

11:00 AM Oxford Style Debate: Commercial teams are prepared to reap the full benefits of advanced digital technologies in 2020 – For & Against

For:

· Advances in AI and machine learning, and an abundance of solutions, are making it easier than ever before for commercial, sales and marketing teams to make digital a core competency

· As the C-suite increasingly values the importance of digital, pharma companies will invest in using digital solutions to guide their sales and marketing strategies

Against:

· Pharma companies still lack the innovation, company mindset and cohesive strategy to move from ‘experimenting with digital’ to ‘scaling it across their global commercial teams’

· Legacy systems and data silos will continue to hamper the implementation of digital and data platforms for many years to come

5:00 PM Panel Discussion & Interactive Polling: Defining the CX of the future: How can you build stronger relationships with your customers to create products and services and content that not just meets but exceeds their expectations?

Rapid advances in digital technology and changing customer demands are requiring pharma companies to radically improve their customer journeys. Our expert panel will together explore how new tech, partnerships and an overhaul in internal business models and culture will completely redefine CX within your industry.

· How will your commercial teams’ skillsets and mindsets have to evolve to best serve physicians and patients in the future pharma landscape?

· How can you identify future market trends to build new commercial models that enable your business to thrive?

· How to re-invent your tech infrastructure and internal processes to become more agile and better respond to future customer needs and expectations?

· How can you partner with innovative start-ups to best leverage cutting edge digital engagement tech, such as voice and chat functionalities?